OPK : Summary for Opko Health, Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 44 mins

Opko Health, Inc. (OPK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.81+0.06 (+0.69%)
At close: 4:00PM EST

8.82 0.01 (0.11%)
Pre-Market: 4:27AM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close8.75
Bid8.77 x 200
Ask8.85 x 100
Day's Range8.62 - 8.82
52 Week Range7.99 - 12.15
Avg. Volume4,767,954
Market Cap4.91B
PE Ratio (TTM)-489.44
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    OPKO Spain to Start Trial of Once-A-Year Intra-Articular Injectable for Osteoarthritis

    MIAMI, Feb. 08, 2017-- OPKO Health, Inc. today announced that its wholly owned subsidiary, OPKO Health Spain, has completed development of Enko 1, a patented intra-articular injectable hyaluronic acid ...

  • GlobeNewswire14 days ago

    OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer

    Enhances leadership for RAYALDEE ® with deep industry knowledge in nephrology; refocuses commercial structure on field representatives. MIAMI, Feb. 07, 2017-- OPKO Health, Inc. announced the promotion ...

  • American City Business Journals19 days ago

    Opko Health subsidiary dives into human genome research

    Opko Health (OPK) subsidiary GeneDx is set to collaborate with a nonprofit organization on human genome research. The Deciphering Developmental Disorder study, led by the Wellcome Trust Sanger Institute in partnership with GeneDx, aims to determine the clinical utility of leveraging technologies relating to human cell research to diagnose patients with developmental disorders. Through the DDD study, scientists at the Wellcome Trust Sanger Institute have worked alongside dozens of doctors over the past 4 years to analyze DNA from 13,500 patients with developmental disorders, along with their biological parents.